PRECIGEN, INC. Preferred Stock, Shares Authorized
PRECIGEN, INC. (PGEN) had Preferred Stock, Shares Authorized of 25.00 million shares as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Stockholders' Equity, Number of Shares, Par Value and Other Disclosure › Preferred Stock, Number of Shares, Par Value and Other Disclosure
us-gaap:PreferredStockSharesAuthorized · last filed 2026-08-04
- 2026-06-30: Preferred Stock, Shares Authorized 25.00M shares.
- 2026-03-31: Preferred Stock, Shares Authorized 25.00M shares.
- 2025-12-31: Preferred Stock, Shares Authorized 25.00M shares.
- 2025-07-25: Preferred Stock, Shares Authorized 25.00M shares.
| Period end | Preferred Stock, Shares Authorized |
|---|---|
| 2026-06-30 | 25.00M shares 10-Q · filed 2026-08-04 |
| 2026-03-31 | 25.00M shares 10-Q · filed 2026-05-13 |
| 2025-12-31 | 25.00M shares 10-K · filed 2026-03-25 |
| 2025-07-25 | 25.00M shares 10-Q · filed 2025-11-13 |
| 2025-03-31 | 25.00M shares 10-Q · filed 2025-05-14 |
| 2024-12-31 | 25.00M shares 10-K · filed 2026-03-25 |
| 2023-12-31 | 25.00M shares 10-K · filed 2025-03-19 |
| 2013-08-13 | 25.00M shares 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |